Conditions: Psoriasis
Keywords: Candidates for systemic therapy for psoriasis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1266
Healthy volunteers: no

Brief summary:
This is a Phase IIIb/IV, open label, multicentre study of efalizumab (anti cluster of differentiation \[CD\] 11a recombinant human monoclonal antibody) in participants with moderate to severe plaque psoriasis who have failed to respond to, have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate, and psoralen and ultraviolet A phototherapy (PUVA).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Efalizumab - anti-CD11a recombinant human monoclonal antibody
Intervention descriptions: intervention 1: Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.

Protocol document: